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Changes in cerebral metabolite ratios (CMR) measured on 1H-MRS and changes in cogni-
tive function (CF) are described in subjects commencing combination antiretroviral therapy
(cART), although the dynamics of such changes are poorly understood.
Methods
Neuroasymptomatic, HIV-infected subjects electively commencing cART were eligible.
CMR were assessed in three anatomical voxels and CF assessed at baseline, week 48 and
week 144. Overall differences in absolute change in CMRs and CF parameters between
0–48 and 48–144 weeks were assessed.
Results
Twenty-two subjects completed study procedures. Plasma HIV-RNA was<50 copies/mL in
all at week 48 and in all, but two subjects at week 144. In general, between weeks 0–48 a
rise in N-acetyl-aspartate(NAA)/Creatine(Cr) ratio and a decline in myo-Inositol(mI)/Cr ratio
were observed. Between weeks 48–144, small rises in NAA/Cr ratio were observed in two
anatomical voxels, whereas a rise in mI/Cr ratio was observed in all anatomical locations
(0.31 (0.66) and -0.27 (1.35) between weeks 0–48 and 0.13 (0.91) and 1.13 (1.71) between
weeks 48–144 for absolute changes in NAA/Cr and mI/Cr (SD) in frontal-grey voxel, respec-
tively). Global CF score improved between weeks 0–48 and then declined between weeks
48–144 (0.63 (1.16) and -0.63 (0.1.41) for mean absolute change (SD) between weeks
0–48 and weeks 48–144, respectively).
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Conclusions
The direction of change of cerebral function parameters differs over time in HIV-infected
subjects commencing cART, highlighting the need for long-term follow-up in such studies.
The changes we have observed between weeks 48–144 may represent the initial develop-
ment of cerebral toxicities from cART.
Introduction
Cerebral function parameters are reported to improve after the initiation of combination anti-
retroviral therapy (cART). These improvements include changes in measures of cognitive abili-
ty [1,2,3,4] and changes in biomarkers of cerebral function, such cerebral metabolites
measured using proton magnetic resonance spectroscopy (1H-MRS) [5,6,7,8]. However, the
temporal trends in changes of cerebral function parameters are poorly understood with most
data reporting on observations over short periods of time up to 24 or 48 weeks.
Although such initial improvements in cerebral function parameters are described, on-
going cognitive function impairment remains widely reported in effectively treated HIV-in-
fected individuals despite cART [9]. The pathogenesis of this on-going cognitive impairment
remains elusive with proposed mechanisms including a lack of suppression of viral replication
in sanctuary sites, persisting neuro-inflammatory processes despite cART and neuronal toxici-
ties secondary to antiretroviral agents [10]. Longitudinal clinical data may be of assistance in
elucidating the natural history of cerebral function in treated HIV-infected subjects and may
assist as supporting data aiding the description of the likely underlying
pathogenic mechanisms.
We assessed the dynamics of change in cerebral function parameters in HIV-infected indi-
viduals over 144 weeks after electively commencing cART.
Methods
Subject selection and study procedures
Neuro-asymptomatic, antiretroviral naïve, HIV-infected subjects attending 4 clinical sites
(St. Mary’s Hospital, London, UK; Queen Elizabeth Hospital, Kowloon, Hong Kong; HIVNAT,
Bangkok, Thailand; Southern Alberta HIV clinic, Calgary, Canada) entering the ALTAIR study
(A Randomised, Open-Label Study Comparing the Safety and Efficacy of Three Different
Combination Antiretroviral Regimens as Initial Therapy for HIV Infection, http://clinicaltrials.
gov/show/NCT00335322 [11]) were eligible to enter a 3 year sub-study. Ethics approval was
granted for all clinical sites in this study and all study participants provided written
informed consent.
At study entry, subjects were randomly allocated to commence cART, comprising tenofo-
vir/emtricitabine 300/200 mg once daily with either efavirenz 600 mg once daily (arm1), ataza-
navir/ritonavir 300/100 mg once daily (arm2), or zidovudine/abacavir 250 or 300 mg twice
daily/600 mg once daily (arm3). After 48 weeks, the primary endpoint of the main study re-
vealed poorer virological response rates in arm3 [11], and thereafter all subjects in this arm
modified antiretroviral therapy based on investigator choice.
Full study entry criteria have previously been reported [12]. Of note, specific exclusion crite-
ria included current or recent use of antidepressant or antipsychotic therapies, established de-
mentia and viral hepatitis C infection (hepatitis C antibody positive).
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Cerebral 1H Magnetic Resonance Spectroscopy
1H-MRS was performed on a 1.5 Tesla Phillips Achieva scanner (Imperial College, London,
London, UK), a 3.0 Tesla Siemens Avanto scanner (Queen Elizabeth Hospital Site, Kowloon,
Hong Kong), a 1.5 Tesla Signa General Electric scanner (HIVNAT site, Bangkok, Thailand)
and a 3.0 Tesla Signa Excite scanner (South Alberta HIV clinic, Calgary, Canada) in three ana-
tomical locations as follows; right frontal white matter (FWM), mid-frontal grey matter (FGM)
and the right basal ganglia (RBG). Detailed descriptions of the precise anatomical locations are
previously reported [12,13]. All spectra were analysed and quantified by one observer (AW)
using a Java-based version of the Magnetic Resonance User Interface package (jMRUI Version
Number: 3.0) incorporating the AMARES algorithm [14]. Metabolites assessed were N-acetyl-
aspartate (NAA), creatine (Cr), choline (Cho) and myo-Inositol (mI). To adjust for different
MRI scanners across sites, all metabolites were expressed as cerebral metabolite ratios (CMR)
with respect to cerebral Cr.
Cognitive testing
Cognitive testing was assessed at baseline and weeks 24, 48 and 144. A computerised cognitive
test battery was utilised (CogState; Melbourne, Australia). This battery has been described in
detail [15] and validated in HIV-disease [16]. This battery contains tasks which are adaptations
of standard neuropsychological tests and assess a range of cognitive functions including the fol-
lowing domains: detection, identification, monitoring and matched learning (all assessed via
speed of test); associate learning and working memory (assessed via accuracy of test); and exec-
utive function (assessed via number of errors made on testing). All study participants complet-
ed one full practice test prior to undertaking the study examination in order to minimise
learning effects [17].
Statistical analysis
Statistical analyses were conducted with Stata version 12 (Statacorp, College Station, TX, USA)
and analysis conducted according to Cogstate recommendations. Changes in cognitive scores
were calculated for each subject, and these scores standardised according to the within-subjects
standard deviation (SD). Composite scores were calculated overall and for the speed, accuracy
and executive function domains based on the average of standardised scores and composite
changes from baseline to week 48 and weeks 48 to 144 were calculated on the average of stan-
dardised scores. The global composite score reflects declines in speed and errors, and improve-
ments in accuracy.
Overall differences in absolute change CMRs between 0–48 and 48–144 weeks were as-
sessed. Regression models were used to estimate the mean absolute differences in CMR and
composite cognitive scores between 0–48 and 48–144 weeks, and to test whether efavirenz use
influenced the changes. In these analyses, P values were adjusted for nine comparisons (3 me-
tabolite ratios in 3 brain regions). Spearman’s rank correlation coefficient was used to test asso-
ciations between changes in cognitive test scores.
Due to small numbers, all analyses were conducted for the entire patient cohort with no
analyses between study treatment arms undertaken. As efavirenz use has been associated with
poorer cognitive function [18], the effect of changing to efavirenz after 48 weeks, on cognitive
function and CMR, was examined in sensitivity analyses using a random effects regression
model. Another sensitivity analysis was undertaken, excluding subjects with a missing plasma
viral load at week 144.
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Results
Patient characteristics
Of 30 subjects enrolled, 22 subjects completed the week 144 study visit. Of those participants
who did not continue to the week 144 visit, reasons for study discontinuation were as follows;
1H MRS could not be scheduled within the window (n = 2), 1H MRS scanner was unavailable
(n = 3), 1H MRS scan unsuccessful (n = 1) and patients were not contactable (n = 2).
Antiretroviral treatment history and HIV-disease parameters are shown on Table 1. Other
baseline characteristics have been described in detail previously [12]. Changes in cerebral me-
tabolite ratios and cognitive function for the 30 recruited subjects over 48 weeks have been pre-
viously reported [12]. Here we report these changes for the 22 subjects completing 144 weeks
of follow up.
Changes in cerebral metabolite ratios over 144 weeks
Between weeks 0 and 48, a rise in neuronal CMR (NAA/Cr) and a decline in inflammatory
CMR (Cho/Cr and mI/Cr) were observed (Table 2). This pattern was observed for all CMR
apart from Cho/Cr in the FGM where only a small absolute change over 0–48 weeks
was observed.
Between weeks 48–144, small increases in neuronal CMR were also observed in the frontal
voxels. Conversely, a decline in neuronal CMR was observed in the basal ganglia and a rise in
Table 1. Subject characteristics (n = 22).
Parameter Value
CD4 count
Baseline CD4 count, (cells/μL, median
/ IQR)
238 176–260
Week 48 CD4 count, (cells/μL, median
/ IQR)
445 274–500




HIV-1 RNA baseline, (log10 copies/mL,
SD)
4.72 0.70
HIV-1 RNA < 50 copies/mL at week
48 (n)
22












IQR = interquartile range, SD = standard deviation, ‘r’ = ritonavir
*Data from two patients were missing at week 144
doi:10.1371/journal.pone.0118608.t001
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inflammatory CMR observed in all anatomical locations. However, the exception was the Cho/
Cr in FGM where only a small absolute change was observed. The dynamics of CMR changes
in frontal white matter over time are shown in Fig. 1.
Changes in cognitive function parameters over 144 weeks
Initially (between weeks 0 to 48), overall cognitive function score improved (mean absolute
change in global score of 0.627, p = 0.02) and improvement in all composite domains
were observed.
Again, on the converse, between weeks 48 to 144 a different pattern was observed. Overall
global cognitive score deteriorated (mean absolute change in global score of -0.629, p = 0.06)
with composite accuracy (-0.305, p = 0.01) and executive function (0.351, p = 0.19) scores also
deteriorating. However there a slight improvement in composite speed observed (-0.027, p =
0.79).
Associations between changes in cerebral function parameters between
weeks 48 and 144
Reductions in NAA/Cr ratio (week 48–144) in RBG were associated with an increase in com-
posite speed score change (week 48–144), Spearman’s Correlation r = 0.50, p = 0.05. No other
statistically significant changes in CMRs between week 48–144 were associated with significant
changes in cognitive function parameters (p>0.10 all observations).
Of the two sensitivity analyses conducted, the first employed a random effects regression
model to investigate whether changes in test parameters could be attributed to changing to an
efavirenz containing regimen after week 48. In these analyses, no effect on cognitive test scores
was noted in subjects who changed to efavirenz. The Cho/Cr ratio in the FFM was lower
Table 2. Changes in cerebral function parameters over 3 years.
Details Mean absolute change Mean absolute change
number week 0–48 SD P-value week 48–144 SD P-value
Cerebral Metabolite Ratio
Anatomical area Ratio
Frontal Grey NAA/Cr 22 0.31 0.66 0.36 0.13 0.91 1.00
Cho/Cr 22 0.02 0.19 1.00 0.09 0.28 1.00
mI/Cr 21 -0.27 1.35 1.00 1.13 1.71 0.06
Frontal White NAA/Cr 22 0.04 0.74 1.00 0.14 0.77 1.00
Cho/Cr 22 -0.08 0.30 1.00 0.14 0.24 0.09
mI/Cr 21 -0.50 1.54 1.00 1.49 1.49 0.002
Right Basal Ganglia NAA/Cr 20 0.64 1.20 0.27 -0.61 1.13 0.27
Cho/Cr 20 -0.09 0.76 1.00 -0.17 0.33 0.27
mI/Cr 20 -0.03 1.05 1.00 0.71 1.46 0.36
Cognitive test parameter
Composite speed score decline in score represents improvement 21 -0.186 0.486 0.10 -0.027 0.452 0.79
Composite accuracy score increase in score represents improvement 21 0.220 0.497 0.06 -0.305 0.499 0.01
Executive function score decline in score represents improvement 21 -0.222 0.858 0.25 0.351 1.20 0.19
Global composite score increase in score represents improvement 21 0.627 1.16 0.02 -0.629 1.41 0.06
SD = standard deviation, NAA/Cr = N-acetyl-aspartate/Creatine, Cho/Cr = Choline/Cr, mI/Cr = myo-Inositol/Cr. P-values <0.05 shown in bold.
doi:10.1371/journal.pone.0118608.t002
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(coefficient -0.26 (95%CI -0.48 to -0.05) and mI/Cr in RBG was higher (coefficient 1.24
(0.28 to 2.18) in subjects with a late switch to efavirenz, but these effects were no longer signifi-
cant after adjusting for multiple comparisons. In the second sensitivity analysis excluding 2 sub-
jects with a missing plasma HIV RNA at week 144, the change coefficients from week 48 to
Fig 1. Dynamics of changes in cerebral metabolite ratios in the Frontal White matter over 3 years.
Fig. 1A: Mean changes in N-acetyl-aspartate/Creatine ratio; Fig. 1B: Mean changes in Choline/Creatine ratio
and Fig. 1C: Mean changes in myo-Inositol/Creatine ratio (error bars represent 1 standard error).
doi:10.1371/journal.pone.0118608.g001
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144 were approximately the same in direction and magnitude for each neurocognitive parame-
ter and metabolite ratio change.
Discussion
In HIV-infected subjects electively commencing cART for the first time, changes in cerebral
function parameters are present and are dynamic with the direction of change differing
over time.
In our study we assessed cerebral function parameters which have been widely utilised in
this field. The computerised cognitive assessment battery (CogState) has been specifically vali-
dated in HIV-disease [16]. Close correlations between measures of cognitive function and mea-
surements of CMR via 1H-MRS have been described in HIV-disease historically, prior to the
advent of antiretroviral therapy [19], and in more recent years in several stages of the disease
course including primary HIV-infection [20], and chronic HIV-infection both prior to the ini-
tiation of cART and in subjects on stable therapy [21,22].
We would consider the initial changes in cerebral function parameters observed over
48 weeks to be representative of improvements. For instance, test scores of cognitive function
all improved. The changes we observed in cerebral metabolites in the current study may repre-
sent a reversal of differences in these parameters which have been reported in untreated HIV-
infected subjects compared to matched control populations [5]. However, in common with
previous published studies, we do not have imaging data in these individuals prior to HIV-in-
fection to confirm that these changes are a reversal of HIV-associated impairment.
Unlike the improvements observed over the first 48 weeks, there was a decline in measures
of cerebral function of the 48 to 144 week period. For instance, global composite cognitive
score deteriorated (-0.629, p = 0.06). Although this change in composite cognitive score was
not statistically significant, this change was greater than 0.5, a z-score difference which previ-
ous work has suggested would be of clinical relevance [23]. A statistically significant deteriora-
tion in cognitive domains measured by accuracy scores was also observed (change 0.499, p =
0.01) between week 48 and 144.
To explain this deterioration in cognitive function during weeks 48–144, one could postu-
late that early on in our study, cognitive testing occurred frequently with a practice test before
study entry and then testing at baseline, week 24 and 48. Two years following, only one test was
undertaken at week 144 and therefore any practice effect may be less marked. However, there
are several counterintuitive arguments to this suggestion. First, subjects did undergo a short
practice test prior to undertaking each cognitive assessment on the computerised battery at
every visit, including the week 144 visit. Second, a lack of practice effect at the week 144 visit
would not explain the changes in CMR observed between week 48–144 and the association be-
tween the reduction in NAA/Cr ratio observed in the BRG with change in composite speed
score. Therefore, the frequency of test completion is unlikely to explain the observed neurocog-
nitive decline post-week 48.
A further explanation could be related to the type of antiretroviral regimens patients were
receiving in our study. Due to arm3 being discontinued after 48 weeks, more subjects were re-
ceiving efavirenz by week 144 (n = 10), compared to the number receiving efavirenz (n = 6) at
week 48. Use of efavirenz has been associated with poorer measures of cognitive function with-
in a cohort setting [18]. Although a sensitivity analysis does not show that efavirenz use was
driving any of our findings, we cannot exclude this cofounder in this small study.
Several causes of variability in cerebral 1H MRS measurements, such as inaccurate voxel re-
localisation and inter-scanner variability, could have influenced our findings [24]. In order to
minimise the effects of voxel re-localisation, during the baseline study scan, voxel placement
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PLOSONE | DOI:10.1371/journal.pone.0118608 February 27, 2015 7 / 10
was based on a study operations manual. Thereafter, on subsequent study scans, voxel place-
ment was undertaken utilising anatomical images of the exact voxel position for each individu-
al subject obtained during the baseline scan. We have minimised any inter-scanner effects by
expressing all 1H MRS measurable parameters as CMR and conducted sensitivity analyses to
ensure no specific scanner in this multicentre study was driving any of the study findings.
Laboratory models using sensitive indices of neural damage have reported toxicities to en-
sure with many antiretroviral agents in current clinical use [10]. It is possible that the effects
we have observed are secondary to such mechanisms. Indeed, the observations we have made
on cerebral 1H MRS, namely a reduction in neuronal metabolite markers and a rise in inflam-
matory metabolite markers, would be supportive of this hypothesis. A previous cerebral 1H
MRS study has reported a reduction in markers of neuronal integrity to be associated with nu-
cleoside-reverse-transcriptase (NRTI) containing antiretroviral therapies in HIV-infected sub-
jects and suggest such changes may be related to mitochondrial toxicities associated with NRTI
use [25]. In our study, all subjects received dual-NRTI based antiretroviral regimens, as per
standard clinical practice, and of interest 8 subjects allocated to arm3 of the study received tri-
ple-NRTI therapy for the first 48 weeks. Our study did not involve measures of antiretroviral
drug exposure, either in the plasma or cerebrospinal fluid compartments and therefore we are
not able to correlate markers of drug exposure with the cerebral metabolite markers we have
measured which in future studies may add further credence to this hypothesis.
Our work will assist in the design of future studies in this field and of importance highlight
the need for longitudinal studies to be of sufficient duration to observe not only the initial ef-
fects of commencing antiretroviral therapy on cerebral function but to also allow adequate fol-
low-up periods in order to observe the on-going effects cART may have longer term in chronic
HIV-disease.
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